New immunotherapy cocktail takes on tough liver tumors
NCT ID NCT07175441
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether adding an experimental drug called RBS2418 to a standard immunotherapy regimen (tremelimumab plus durvalumab) can better control advanced liver cancer that cannot be removed by surgery. About 220 adults will receive either the combination or the standard therapy alone. The main goal is to see if the combination delays cancer progression and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RBS2418 combined with tremelimumab and durvalumab (immunotherapy drugs)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for advanced liver cancer, potentially slowing tumor growth and extending survival.
- What could go wrong
- This is an early Phase 2 trial with only 220 participants, so results may not apply to all patients. The added drug RBS2418 may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21218, United States
-
START Dallas Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.